Mankind pharma share price

• • Invest • • • • • Stock Screener (i-Lens) • • Markets App • • • • • • • • Budget 2023 • • Invest • • Top Mutual Funds • • • • • • • • • Invest • • • My Watchlist • • • • • Invest • • • • • • • Invest • • • • • • • Invest • • • • Invest • • • • One Assist • • • • • • Invest • • • • • • • • • Real Estate Investment Trust • • • • • • • • • • Investonomics • • • • • • • • • • • • • • • • • • • • • • • • • • Description • Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name "Mankind Pharma Private Limited", by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of `Amlokind` tablets and `Glimestar` tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophth...

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. EXEL: What does Argus have to say about EXEL?EXELIXIS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low. GlobeNewswire Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®. Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build ou InvestorPlace 7 Overvalued Penny Stocks to Sell Before June 2023 While there are plenty of bargains to buy among penny stocks, there are also a good amount of overvalued penny stocks to sell. Whil...

The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing to pay, whereas the ask is the lowest ... Read More. amount that a seller is currently willing to sell. The numbers next to the bid/ask are the “ size”. The bid size displays the total amount of desired shares to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time. The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a market order or limit order when trading, helping you to optimize your price and have a successful order execution. Real-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit Nasdaq Data Link's products page. ... Read Less. Label Value Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly volunt...

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time). DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions. By using this site, you agree to the Terms of Service and Privacy Policy.

JPMorgan initiated coverage on the new listing with an overweight rating and a price target of Rs 1,700 per share. The price target implies a potential upside of 15 percent from Monday's closing levels.The firm believes that India’s fourth-largest pharmaceutical company will continue to gain market share, driven by its strong product portfolio and large distribution network.